Gablofen approved for severe spasticity

The FDA has approved Gablofen (baclofen for intrathecal injection, from CNS Therapeutics), a centrally active muscle relaxant, for the management of severe spasticity. Gablofen is expected to be available in 50mcg/mL, 500mcg/mL, and 2,000mcg/mL concentrations in ready-to-use vials or pre-filled syringes by early to mid-December 2010.

For more information call (651) 207-6959 or visit www.gablofen.com.